Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
111
City of Hope Medical Center
Duarte, California, United States
UCLA Medical Center
Los Angeles, California, United States
Loyola University
Maywood, Illinois, United States
Clinical safety as measured by the recording of treatment emergent adverse events
Time frame: 13 weeks
Incidence of CMV disease
Time frame: 13 weeks
Incidence of CMV infection
Time frame: 13 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tufts-New England Medical Center
Boston, Massachusetts, United States
Wayne State Medical Center
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Duke Medical Center
Durham, North Carolina, United States
Baylor University Medical Center
Dallas, Texas, United States
...and 3 more locations